The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Effect of Antiviral Treatment on the Outcome of Secondary Bacterial Pneumonia after Influenza
Abstract
Secondary bacterial pneumonia is an important cause of influenza-associated death. Although antibacterial therapy is standard, antiviral therapy has been ignored because viral infections usually resolve by the time bacterial pneumonia presents. In the present study, antiviral compounds were tested in a mouse model of secondary pneumococcal pneumonia after influenza. Treatment with oseltamivir improved survival in mice from 0% to 75%, even when therapy was delayed for up to 5 days after infection with influenza virus. In mice, treatment with rimantadine had no effect on survival. Treatment with ampicillin cleared infection but, in the absence of treatment with oseltamivir, did not improve survival. Pneumonia developed in only 7 of the 22 mice receiving oseltamivir, and subsequent treatment with ampicillin resulted in cure (100% survival). Treatment of the predisposing influenza-virus infection with inhibitors specific for the viral neuraminidase may improve the efficacy of antibiotics and increase survival in persons who are at high risk for complications and mortality during influenza.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371302 · Cited by 762
Oral oseltamivir treatment of influenza in children
WHITLEY, R. J., HAYDEN, F. G., REISINGER, K. S., YOUNG, N., DUTKOWSKI, R., IPE, D., MILLS, R. G., & WARD, P. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200102000-00002 · Cited by 711
Effectiveness of Pneumococcal Polysaccharide Vaccine in Older Adults
Jackson, L. A., Neuzil, K. M., Yu, O., Benson, P., Barlow, W. E., Adams, A. L., Hanson, C. A., Mahoney, L. D., Shay, D. K., & Thompson, W. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022678 · Cited by 608 · cited 1×
“Vaccination against influenza prevents hospitalizations for pneumonia in elderly adults [20–22], whereas vaccination with only 23-valent pneumococcal vaccine is not effective [23].”
BackgroundUse of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza
Hayden, F. G., Atmar, R. L., Schilling, M., Johnson, C., Poretz, D., Paar, D., Huson, L., Ward, P., & Mills, R. G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411802 · Cited by 512
Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens.
Nichol, K. L., Wuorenma, J., & von Sternberg, T. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.16.1769 · Cited by 484
McCullers, J. A., & Rehg, J. E. (2002) · The Journal of Infectious Diseases · doi:10.1086/341462 · Cited by 423
Self-citationClinical effectiveness of influenza vaccination in Manitoba.
Fedson, D. S. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510160074032 · Cited by 278
Plotkowski, M.-C., Puchelle, E., Beck, G., Jacquot, J., & Hannoun, C. (1986) · American Review of Respiratory Disease · doi:10.1164/arrd.1986.134.5.1040 · Cited by 231
Bacterial adherence to pharyngeal cells during viral infection.
Fainstein, V., Musher, D. M., & Cate, T. R. (1980) · Journal of Infectious Diseases · doi:10.1093/infdis/141.2.172 · Cited by 177
THE RELATION OF INFLUENZA VIRUS AND BACTERIA IN THE ETIOLOGY OF PNEUMONIA 12
Maxwell, E. S., Ward, T. G., & Van Metre, T. E. (1949) · Journal of Clinical Investigation · doi:10.1172/jci102073 · Cited by 37 · cited 1×
“when, for example, the case-fatality rate in confirmed cases of influenza was 380Zo [1, 14-16]?and to those of”
Background
Cited by
Insights into the Interaction between Influenza Virus and Pneumococcus
McCullers, J. A. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-05 · Cited by 846
Self-citationThe co-pathogenesis of influenza viruses with bacteria in the lung.
McCullers, J. A. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3231 · Cited by 722
Self-citationMcAuley, J. L., Hornung, F., Boyd, K. L., Smith, A. M., McKeon, R., Bennink, J., Yewdell, J. W., & McCullers, J. A. (2007) · Cell Host & Microbe · doi:10.1016/j.chom.2007.09.001 · Cited by 389
“…that influenza infection prior to bacterial superinfection causes a synergistic increase in the cytokine response with a resultant adverse outcome (Smith et al., 2007), and treatment of secondary pneumonia by antibiotic-mediated lysis of pneumococcus does not reduce mortality (McCullers, 2004).”
BackgroundMethodMetersky, M. L., Masterton, R. G., Lode, H., File, T. M., & Babinchak, T. (2012) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2012.01.003 · Cited by 293
“Treatment with the M2 ion-channel inhibitor rimantadine had no effect on survival.(79) Furthermore, a prospective cohort study of patients (n = 310) admitted to Ontario hospitals with laboratory-confirmed”
BackgroundSiegel, S. J., Roche, A. M., & Weiser, J. N. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.06.005 · Cited by 247
“, 2012), but experiments in mice demonstrated survival benefits to neuraminidase inhibitor treatment during coinfection even at later time points when there was no effect on viral replication (McCullers, 2004).”
BackgroundResultInfluential
Metadata
- Authors
- McCullers, J. A.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08
- Volume
- 190
- Issue
- 3
- Pages
- 519-526
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2145665328
- Cited by
- 162
- References
- 10
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.